Literature DB >> 33457207

Recurrent rhabdomyolysis and exercise intolerance: A new phenotype of late-onset thymidine kinase 2 deficiency.

Carlos Pablo de Fuenmayor-Fernández de la Hoz1, Germán Morís2, Cecilia Jiménez-Mallebrera3,4, Carmen Badosa3, Aurelio Hernández-Laín5, Alberto Blázquez Encinar4,6,7, Miguel Ángel Martín4,6,7, Cristina Domínguez-González1,4,6.   

Abstract

A 29-year-old man developed, since the age of 18, exercise intolerance and exercise-induced rhabdomyolysis, with myoglobinuria. Muscle biopsy showed ragged-red fibers. Multiple mitochondrial DNA deletions were detected. The previously reported pathogenic homozygous mutation c.323C>T (p.Thr108Met) in TK2 was identified. This case expands the phenotypic spectrum of TK2 deficiency and indicates that it should be considered in the differential diagnosis of episodic rhabdomyolysis and exercise intolerance, along with other metabolic and mitochondrial myopathies. Since a new treatment is under development, it is essential improving knowledge of the natural history of TK2 deficiency.
© 2020 The Authors.

Entities:  

Year:  2021        PMID: 33457207      PMCID: PMC7797901          DOI: 10.1016/j.ymgmr.2020.100701

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


Introduction

Thymidine kinase 2 (TK2) is a nuclear-encoded mitochondrial enzyme that phosphorylates the pyrimidine nucleosides thymidine (dT) and deoxycytidine (dC) to generate their nucleoside monophosphates. TK2 is essential in the deoxynucleoside triphosphate salvage synthesis pathway in quiescent cells, and its deficiency cause mitochondrial depletion / multiple deletion syndrome [1,2]. Recessive mutations in the TK2 gene cause primarily a mitochondrial myopathy with a broad spectrum of age of onset and severity [3]: from extremely severe and rapidly progressive infantile-onset forms, with survival under two years, linked to mitochondrial DNA (mtDNA) depletion (MIM# 609560), to less severe forms with later onset and a slower rate of progression, associated to mtDNA multiple deletions. Late-onset patients, previously defined as patients where symptoms starts after the age of 12 [3], display a phenotype consisting of progressive proximal limb, axial, neck flexor and facial muscle weakness, frequently associated with ptosis, ophthalmoparesis and bulbar weakness, along with an early and severe respiratory involvement [4]. In some cases, chronic late-onset progressive external ophthalmoplegia is the main manifestation (MIM# 617069) [5]. We report a patient with TK2 deficiency presenting with recurrent rhabdomyolysis, myoglobinuria and exercise intolerance. Since a new treatment is under development [6] (ClinicalTrials.gov Identifier NCT03845712), it is essential improving knowledge of the natural history of TK2 deficiency.

Methods

All procedures were conducted as part of routine clinical care. The patient underwent clinical evaluation, muscle magnetic resonance imaging (MRI), muscle biopsy and genetic analysis by a customized next generation sequencing (NGS) panel. Patient's skeletal muscle mitochondrial DNA (mtDNA) deletions were investigated by Southern blot, and mtDNA copy number was assessed by quantitative polymerase chain reaction (PCR). Written informed consent was obtained for the genetic study. Anonymized data from this study will be shared by request from qualified investigators.

Results

The patient is a 29-year-old man born from non-consanguineous parents. He had a normal development and had no symptoms during infancy and childhood. HyperCKemia was detected for the first time when the patient was 16 years old. At the age of 18, he had the first exercise-induced rhabdomyolysis episode. Since then, he developed exercise intolerance characterized by disproportionate fatigue during physical activity of any intensity and recurrent episodes of rhabdomyolysis with myoglobinuria. Although the patient did not complain of weakness, on examination he had mild bilateral facial weakness involving only orbicularis oculi, and muscle strength testing revealed mild bilateral weakness in hip extension and knee flexion (4+/5 on the Medical Research Council scale) in lower limbs, and in fingers extension (4/5) in upper limbs. The rest of the examination was normal. He had no ptosis, no ophthalmoparesis, and no bulbar, axial or neck flexion weakness. There was no muscle atrophy. Deep tendon reflexes were normal. Basal serum creatine kinase levels were increased (615–931 U/l, normal range: 34–171 U/l). Spirometry, electrocardiogram and echocardiogram were normal. Lower-limb muscle Magnetic Resonance Imaging (Fig. 1) showed a severe and symmetrical fatty infiltration of gluteus maximus (Mercuri visual scale modified by Fisher, MVS: 3), mild and diffuse fat muscle substitution at thighs and legs (MVS: 1–2), which was predominant in posterior compartments, and affectation of sartorius (MVS: 2). Muscle biopsy (quadriceps) showed numerous COX-negative, ragged-red fibers and no dystrophic features. Mild variability in fiber size, and mild nuclear internalization were observed, as well as one isolated necrotic fiber. Respiratory chain complexes activities were normal. Muscle mtDNA analysis revealed multiple mtDNA deletions (Fig. 2) and decreased mtDNA/nuclear DNA copy-number ratio (48% respect to controls; mtDNA depletion cut-off < 30%). Serum levels of growth differentiation factor-15 (GDF-15) were 1503–2525 pg/ml (upper normal limit, 550 pg/ml). A previously reported pathogenic homozygous mutation c.323C>T (p.Thr108Met) in the TK2 gene was identified by a NGS panel.
Fig. 1

T1-weighted MRI of lower limbs. A: pelvis. Symmetrical fat infiltration of gluteus maximus (MVS: 3), which is the most severely affected muscle. Bilateral involvement of tensor fascia latae is also observed (MVS: 2). B: thighs. Mild and diffuse fat muscle substitution (MVS: 1–2), which is predominant in posterior compartments. Sartorius is bilaterally affected by fat infiltration (MVS: 2). C: legs. Very mild and diffuse fat muscle substitution.

s: sartorius, rf: rectus femoris, tfl: tensor fascia latae, ips: iliopsoas, pc: pectinius, oe: obturator externus, oi:obturator internus, gma: gluteus maximus, vl: vastus lateralis, vi: vastus intermedius, vm: vastus medialis, g: gracilis, am: adductor magnus, st: semitendinosus, sm: semimembranosus, bf: biceps femoris, ta: tibialis anterior, ehl: extensor hallucis longus, edl: extensor digitorium longus, pl: peroneus longus, tp: tibialis posterior, fdl: flexor digitorium longus, fhl: flexor hallucis longus, so: soleus, gl: gastrocnemius lateralis, gm: gastrocnemius medialis.

Fig. 2

Patient's skeletal muscle showing multiple mitochondrial DNA deletions. Southern blot analysis of muscle mitochondrial DNA to detect mtDNA reorganizations. Lane 1, control muscle DNA showing the normal 16.5 Kb size of mtDNA; Lane 2, TK2-patient displaying normal sized mtDNA and multiple mtDNA deletions; Lane 3, positive control for mtDNA deletions; Lane 4, molecular weight marker.

T1-weighted MRI of lower limbs. A: pelvis. Symmetrical fat infiltration of gluteus maximus (MVS: 3), which is the most severely affected muscle. Bilateral involvement of tensor fascia latae is also observed (MVS: 2). B: thighs. Mild and diffuse fat muscle substitution (MVS: 1–2), which is predominant in posterior compartments. Sartorius is bilaterally affected by fat infiltration (MVS: 2). C: legs. Very mild and diffuse fat muscle substitution. s: sartorius, rf: rectus femoris, tfl: tensor fascia latae, ips: iliopsoas, pc: pectinius, oe: obturator externus, oi:obturator internus, gma: gluteus maximus, vl: vastus lateralis, vi: vastus intermedius, vm: vastus medialis, g: gracilis, am: adductor magnus, st: semitendinosus, sm: semimembranosus, bf: biceps femoris, ta: tibialis anterior, ehl: extensor hallucis longus, edl: extensor digitorium longus, pl: peroneus longus, tp: tibialis posterior, fdl: flexor digitorium longus, fhl: flexor hallucis longus, so: soleus, gl: gastrocnemius lateralis, gm: gastrocnemius medialis. Patient's skeletal muscle showing multiple mitochondrial DNA deletions. Southern blot analysis of muscle mitochondrial DNA to detect mtDNA reorganizations. Lane 1, control muscle DNA showing the normal 16.5 Kb size of mtDNA; Lane 2, TK2-patient displaying normal sized mtDNA and multiple mtDNA deletions; Lane 3, positive control for mtDNA deletions; Lane 4, molecular weight marker.

Discussion

This is the first description of a patient with TK2 deficiency presenting with recurrent rhabdomyolysis and exercise intolerance. They keep being the main manifestations after more than 10 years from the onset of symptoms. It corresponds, therefore, with a milder phenotype than those previously described. GDF-15 is a biomarker which was shown to correlate with severity of TK2 deficiency. It is elevated on average 30-fold in children and 6-fold in adults [7]. The degree of increase in GDF-15 levels in our patient (3-5-fold) is also consistent with a milder phenotype, and supports the idea of the prognostic value of GDF-15 levels in TK2 deficiency. Since initial manifestations in our patient were earlier than in patients with more severe symptoms, the age of onset is not enough to establish, by itself, the prognosis. On lower-limb muscle MRI, gluteus maximus was the most severely affected muscle, and sartorius, a muscle which is usually spared in many genetic muscle diseases (even in late stages), was also affected. Interestingly, these MRI fits with a pattern previously described in late-onset TK2 patients [4]. In conclusion, this case expands the phenotypic spectrum of TK2 deficiency, which should be considered in the differential diagnosis of episodic rhabdomyolysis and exercise intolerance, along with other metabolic and mitochondrial myopathies, and it suggests that the muscle MRI could help to guide the differential diagnosis in a patient with a metabolic myopathy.

Author statement

CPFF, CDG, MAM were responsable for the conception and design of this report. CPFF, GM, CJM, CB, AH and ABE acquired and analyzed data. CPFF, MAM and CDG drafted the manuscript and figures.
  7 in total

1.  Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions.

Authors:  Henna Tyynismaa; Ren Sun; Sofia Ahola-Erkkilä; Henrikki Almusa; Rosanna Pöyhönen; Mari Korpela; Jari Honkaniemi; Pirjo Isohanni; Anders Paetau; Liya Wang; Anu Suomalainen
Journal:  Hum Mol Genet       Date:  2011-09-21       Impact factor: 6.150

2.  Deoxynucleoside Therapy for Thymidine Kinase 2-Deficient Myopathy.

Authors:  Cristina Domínguez-González; Marcos Madruga-Garrido; Fabiola Mavillard; Caterina Garone; Francisco Javier Aguirre-Rodríguez; M Alice Donati; Karin Kleinsteuber; Itxaso Martí; Elena Martín-Hernández; Juan P Morealejo-Aycinena; Francina Munell; Andrés Nascimento; Susana G Kalko; M Dolores Sardina; Concepcion Álvarez Del Vayo; Olga Serrano; Yuelin Long; Yuqi Tu; Bruce Levin; John L P Thompson; Kristen Engelstad; Jasim Uddin; Javier Torres-Torronteras; Cecilia Jimenez-Mallebrera; Ramon Martí; Carmen Paradas; Michio Hirano
Journal:  Ann Neurol       Date:  2019-06-17       Impact factor: 10.422

3.  Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy.

Authors:  A Saada; A Shaag; H Mandel; Y Nevo; S Eriksson; O Elpeleg
Journal:  Nat Genet       Date:  2001-11       Impact factor: 38.330

Review 4.  Mitochondrial purine and pyrimidine metabolism and beyond.

Authors:  Liya Wang
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2016-12       Impact factor: 1.381

5.  Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy.

Authors:  Cristina Dominguez-Gonzalez; Carmen Badosa; Marcos Madruga-Garrido; Itxaso Martí; Carmen Paradas; Carlos Ortez; Jordi Diaz-Manera; Andres Berardo; Jorge Alonso-Pérez; Selena Trifunov; Daniel Cuadras; Susana G Kalko; Cora Blázquez-Bermejo; Yolanda Cámara; Ramon Martí; Fabiola Mavillard; Miguel A Martin; Julio Montoya; Eduardo Ruiz-Pesini; Joan Villarroya; Raquel Montero; Francesc Villarroya; Rafael Artuch; Michio Hirano; Andrés Nascimento; Cecilia Jimenez-Mallebrera
Journal:  Sci Rep       Date:  2020-06-22       Impact factor: 4.379

6.  Late-onset thymidine kinase 2 deficiency: a review of 18 cases.

Authors:  Cristina Domínguez-González; Aurelio Hernández-Laín; Eloy Rivas; Ana Hernández-Voth; Javier Sayas Catalán; Roberto Fernández-Torrón; Carmen Fuiza-Luces; Jorge García García; Germán Morís; Montse Olivé; Frances Miralles; Jordi Díaz-Manera; Candela Caballero; Bosco Méndez-Ferrer; Ramon Martí; Elena García Arumi; María Carmen Badosa; Jesús Esteban; Cecilia Jimenez-Mallebrera; Alberto Blazquez Encinar; Joaquín Arenas; Michio Hirano; Miguel Ángel Martin; Carmen Paradas
Journal:  Orphanet J Rare Dis       Date:  2019-05-06       Impact factor: 4.303

7.  Retrospective natural history of thymidine kinase 2 deficiency.

Authors:  Caterina Garone; Robert W Taylor; Andrés Nascimento; Joanna Poulton; Carl Fratter; Cristina Domínguez-González; Julie C Evans; Mariana Loos; Pirjo Isohanni; Anu Suomalainen; Dipak Ram; M Imelda Hughes; Robert McFarland; Emanuele Barca; Carlos Lopez Gomez; Sandeep Jayawant; Neil D Thomas; Adnan Y Manzur; Karin Kleinsteuber; Miguel A Martin; Timothy Kerr; Grainne S Gorman; Ewen W Sommerville; Patrick F Chinnery; Monika Hofer; Christoph Karch; Jeffrey Ralph; Yolanda Cámara; Marcos Madruga-Garrido; Jana Domínguez-Carral; Carlos Ortez; Sonia Emperador; Julio Montoya; Anupam Chakrapani; Joshua F Kriger; Robert Schoenaker; Bruce Levin; John L P Thompson; Yuelin Long; Shamima Rahman; Maria Alice Donati; Salvatore DiMauro; Michio Hirano
Journal:  J Med Genet       Date:  2018-03-30       Impact factor: 6.318

  7 in total
  1 in total

1.  Preferent Diaphragmatic Involvement in TK2 Deficiency: An Autopsy Case Study.

Authors:  Sara Laine-Menéndez; Cristina Domínguez-González; Alberto Blázquez; Aitor Delmiro; Inés García-Consuegra; Miguel Fernández-de la Torre; Aurelio Hernández-Laín; Javier Sayas; Miguel Ángel Martín; María Morán
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.